

**Stock Data**

Share Price: 23.50p  
Market Cap: £39.0m  
Shares in issue: 165.9m

**Company Profile**

Sector: Healthcare  
Ticker: DVRG  
Exchange: AIM

**Activities**

DeepVerge plc ('DeepVerge', 'DVRG', 'the Group'), (formerly Integumen plc) is a vertically integrated business, collaborating technology platforms with partners in artificial intelligence, clinical research, water technologies, medical devices and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skincare, healthcare, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

Group website: [www.deepverge.com](http://www.deepverge.com)

**Share price performance from 6 Oct.2020**



Source: [LSE](http://LSE)

**Past performance is not an indication of future performance.**

**Turner Pope contact details**

Turner Pope Investments ("TPI") Limited  
8 Frederick's Place  
London EC2R 8AB

Tel: 0203 657 0050  
Email: [info@turnerpope.com](mailto:info@turnerpope.com)  
Web: [www.turnerpope.com](http://www.turnerpope.com)

**Attention is drawn to the disclaimers and risk warnings at the end of this document.**

This is a non-independent marketing communication. The analyst who has prepared this report is aware that TPI has a relationship with the company covered in this report. Accordingly, it has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

**TPI acts as sole broker to DeepVerge plc.**

**Retail clients (as defined by the rules of the FCA) must not rely on this document.**

**Barry Gibb**  
Research Analyst  
Tel: 0203 657 0050  
[barry.gibb@turnerpope.com](mailto:barry.gibb@turnerpope.com)

**Andrew Thacker**  
Corporate Broking & Sales  
Tel: 0203 657 0050  
[andy.thacker@turnerpope.com](mailto:andy.thacker@turnerpope.com)

**Zoe Alexander**  
Corporate Broking & Sales  
Tel: 0203 657 0050  
[zoe.alexander@turnerpope.com](mailto:zoe.alexander@turnerpope.com)

## DeepVerge plc

**DeepVerge has announced its new R&D service, which was launched in August 2020, has already generated £400,000 in completed sales in Q4 2020. Work agreements have been signed with ten new clients that had previously not used [Labskin](#) services. These agreements include framework Master Services Agreements with two of the world's largest suppliers of consumer products related to skincare. Turner Pope looks forward to DeepVerge delivering further operational progress across its broad range of potentially ground breaking developments in tandem with additional opportunities generated through its [recent takeover of Modern Water plc](#).**

### Real-world clones of the human skin microbiome

Interim results from Labskin's partnership with the University of Aberdeen that were released on [27 November 2020](#), validated its ability to provide access to real-world clones of the human skin microbiome that are capable of simulating costly, time consuming and potentially hazardous clinical testing. By using six different microbial strains in a laboratory setting, Labskin entirely removes the risk of transmission, reaction or injury to human volunteers, by rapidly and economically mirroring the impact of treatments (including probiotics, prebiotics, cosmetics etc.) and therapeutics on real human skin. Significantly, once the University of Aberdeen trials have completed and been verified, labelling authorisation could also be formally granted

Labskin's new R&D service adds to the existing client offering. It increases revenue per client and delivers higher value test services on ingredients used in an expansive range of products – from anti-viral, to shampoos to babies' nappies. The new service replicates skin conditions of the scalp, face, mouth and abdomen. It also utilises AI which has significantly improved the speed and accuracy of testing ingredients on virtual skin models.

### Gerard Brandon, Chief Executive Officer of DeepVerge, noted:

"When we designed this new service we built on three key platforms: Labskin's ability to grow human skin, its expertise in replicating the skin's microbial environment from different parts of the body and its increasing use of AI and data which helps with speed, accuracy and insights. While we will fully launch the product at conferences across all regions in 2021, it has already resulted in significant interest and orders from existing and new clients as well as from new clients in new sectors/markets.

The Labskin division has become a recognised global leader in cloning and testing real-world human skin microbiome in a laboratory with a rapidly expanding order book from a growing blue-chip client base. Since September 2019, the team has increased revenue per client exponentially by offering multiple value-added solutions beyond its core laboratory testing services which lower client development costs of product information validation enabling new products get to market faster."

**THIS DOCUMENT IS NOT FOR PUBLICATION, DISTRIBUTION OR TRANSMISSION INTO THE UNITED STATES OF AMERICA, JAPAN, CANADA OR AUSTRALIA.**

### **Conflicts**

This is a non-independent marketing communication under the rules of the Financial Conduct Authority ("FCA"). The analyst who has prepared this report is aware that Turner Pope Investments (TPI) Limited ("TPI") has a relationship with the company covered in this report. Accordingly, the report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing by TPI or its clients ahead of the dissemination of investment research.

TPI manages its conflicts in accordance with its conflict management policy. For example, TPI may provide services (including corporate finance advice) where the flow of information is restricted by a Chinese wall. Accordingly, information may be available to TPI that is not reflected in this document. TPI may have acted upon or used research recommendations before they have been published.

### **Risk Warnings**

Retail clients (as defined by the rules of the FCA) must not rely on this document.

Any opinions expressed in this document are those of TPI's research analyst. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price.

The value of securities, particularly those of smaller companies, can fall as well as rise and may be subject to large and sudden swings. In addition, the level of marketability of smaller company securities may result in significant trading spreads and sometimes may lead to difficulties in opening and/or closing positions. Past performance is not necessarily a guide to future performance and forecasts are not a reliable indicator of future results.

AIM is a market designed primarily for emerging or smaller companies and the rules of this market are less demanding than those of the Official List of the UK Listing Authority; consequently, AIM investments may not be suitable for some investors. Liquidity may be lower and hence some investments may be harder to realise.

### **Specific disclaimers**

TPI acts as sole broker to DeepVerge plc ('DeepVerge') which is listed on the AIM Market of the London Stock Exchange ('AIM'). TPI's private and institutional clients may hold, subscribe for or buy or sell DeepVerge's securities.

Opinions and estimates in this document are entirely those of TPI as part of its internal research activity. TPI has no authority whatsoever to make any representation or warranty on behalf of DeepVerge.

### **General disclaimers**

This document, which presents the views of TPI's research analyst, cannot be regarded as "investment research" in accordance with the FCA definition. The contents are based upon sources of information believed to be reliable but no warranty or representation, express or implied, is given as to their accuracy or completeness. Any opinion reflects TPI's judgement at the date of publication and neither TPI nor any of its directors or employees accepts any responsibility in respect of the information or recommendations contained herein which, moreover, are subject to change without notice. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price. TPI does not undertake to provide updates to any opinions or views expressed in this document. TPI accepts no liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document (except in respect of wilful default and to the extent that any such liability cannot be excluded by applicable law).

The information in this document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.

This document is approved and issued by TPI for publication only to UK persons who are authorised persons under the Financial Services and Markets Act 2000 and to professional clients, as defined by Directive 2004/39/EC as set out in the rules of the Financial Conduct Authority. This document may not be published, distributed or transmitted to persons in the United States of America, Japan, Canada or Australia. This document may not be copied or reproduced or re-distributed to any other person or organisation, in whole or in part, without TPI's prior written consent.

Copyright © 2020 Turner Pope Investments (TPI) Limited, all rights reserved.